Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

Day JS, Ding M, Bednarz P, van der Linden JC, Mashiba T, Hirano T, Johnston CC, Burr DB, Hvid I, Sumner DR, Weinans H.

J Orthop Res. 2004 May;22(3):465-71.

3.
4.

Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.

Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB.

Calcif Tissue Int. 2005 Sep;77(3):180-5. Epub 2005 Sep 8.

PMID:
16265598
5.

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.

Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT.

Bone. 2006 Aug;39(2):345-52. Epub 2006 Mar 29.

PMID:
16571382
6.

Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.

Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC.

Bone. 2003 Dec;33(6):960-9.

PMID:
14678856
7.

Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.

Yao W, Balooch G, Balooch M, Jiang Y, Nalla RK, Kinney J, Wronski TJ, Lane NE.

Bone. 2006 Sep;39(3):460-9. Epub 2006 May 19.

PMID:
16713415
8.

Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.

Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.

Calcif Tissue Int. 2007 Aug;81(2):73-80.

PMID:
17612779
9.

Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs.

Fischer KJ, Vikoren TH, Ney S, Kovach C, Hasselman C, Agrawal M, Rubash H, Shanbhag AS.

J Biomed Mater Res B Appl Biomater. 2006 Jan;76(1):143-8.

PMID:
16047323
10.

Effects of osteoporosis medications on bone quality.

Benhamou CL.

Joint Bone Spine. 2007 Jan;74(1):39-47. Epub 2006 Nov 28. Review.

PMID:
17196423
11.

Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.

Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T.

Bone. 2013 May;54(1):1-7. doi: 10.1016/j.bone.2013.01.016. Epub 2013 Jan 26.

PMID:
23356990
12.

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.

Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps RJ, Turner RT.

Bone. 2005 Jul;37(1):1-9.

PMID:
15894527
13.
14.

Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL.

Bone. 2010 Mar;46(3):666-72. doi: 10.1016/j.bone.2009.11.011. Epub 2009 Nov 17.

15.

Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.

Bone. 2011 Dec;49(6):1160-5. doi: 10.1016/j.bone.2011.08.015. Epub 2011 Aug 27.

PMID:
21893225
16.

Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?

Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB.

Bone. 2000 Jul;27(1):13-20.

PMID:
10865204
17.

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D.

Osteoporos Int. 2009 Jun;20(6):887-94. doi: 10.1007/s00198-008-0754-4. Epub 2008 Oct 11.

18.

Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.

Spadaro JA, Damron TA, Horton JA, Margulies BS, Murray GM, Clemente DA, Strauss JA.

J Orthop Res. 2006 May;24(5):936-44.

19.

Spatial orientation in bone samples and Young's modulus.

Geraets WG, van Ruijven LJ, Verheij JG, van der Stelt PF, van Eijden TM.

J Biomech. 2008 Jul 19;41(10):2206-10. doi: 10.1016/j.jbiomech.2008.04.016. Epub 2008 Jun 9.

PMID:
18539283
20.

Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.

Allen MR, Follet H, Khurana M, Sato M, Burr DB.

Calcif Tissue Int. 2006 Oct;79(4):255-61. Epub 2006 Oct 10.

Supplemental Content

Support Center